2 Topic Commentaries

FDA Expands Marstacimab Indication in Hemophilia A and B

• 

  Ann Farrell, MD

  Hematology; Drug Evaluation and Research

  •

  U.S. Food and Drug Administration

  Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process. This new type of treatment underscores the FDA’s commitment to advance the development of innovative, safe and effective therapies.

  Source
• 

  Akshat Jain, MD

  Pediatric Hematology/Oncology; Hemophilia

  •

  Loma Linda University Health

  For the first time, patients with Hemophilia B in Southern California have access to a therapy that is not just effective but also drastically improves their daily lives. This marks a monumental shift in treatment, allowing patients to take control of their health in a way that was not possible before.

  Source